Showing results (1-10 of 41) with videos related to
Sort By:
Pageof 5
Expert Opinion on Investigational Drugs|November 4, 2011
Belinostat: clinical applications in solid tumors and lymphomaL Rhoda Molife, Johann S de BonoCritical Reviews in Oncology/Hematology|February 11, 2014
Cancer therapeutics: Targeting the apoptotic pathwayKhurum H Khan, Montserrat Blanco-Codesido, L Rhoda MolifeCurrent Oncology Reports|February 8, 2012
FGF receptor inhibitors: role in cancer therapyGennaro Daniele, Jesus Corral, L Rhoda Molife, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2012
Combining antiangiogenics to overcome resistance: rationale and clinical experienceVictor Moreno Garcia, Bristi Basu, L Rhoda Molife, et al.Current Opinion in Oncology|April 6, 2012
Targeting the DNA damage response in oncology: past, present and future perspectivesBristi Basu, Timothy A Yap, L Rhoda Molife, et al.Expert Opinion on Drug Discovery|March 15, 2013
Targeting cell cycle kinases and kinesins in anticancer drug developmentTimothy A Yap, L Rhoda Molife, Sarah P Blagden, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2011
Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?Sophie Postel-Vinay, Carlos Gomez-Roca, L Rhoda Molife, et al.Nature Reviews. Clinical Oncology|April 7, 2011
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancerMartin D Forster, Konstantin J Dedes, Shahneen Sandhu, et al.Oncology|October 12, 2011
Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trialsMontserrat Blanco Codesido, Andre Tesainer Brunetto, Sophia Frentzas, et al.Cancer Chemotherapy and Pharmacology|March 13, 2009
A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumoursEdwina N Scott, Anne L Thomas, L Rhoda Molife, et al.Pageof 5